131 related articles for article (PubMed ID: 35383042)
1. SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis.
Garcia P; Han J; Montez-Rath ME; Sun S; Shang T; Parsonnet J; Chertow GM; Anand S; Schiller B; Abra G
Clin J Am Soc Nephrol; 2022 Jul; 17(7):1036-1038. PubMed ID: 35383042
[No Abstract] [Full Text] [Related]
2. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
3. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
4. Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis.
Anand S; Montez-Rath ME; Han J; Garcia P; Cadden L; Hunsader P; Kerschmann R; Beyer P; Dittrich M; Block GA; Boyd SD; Parsonnet J; Chertow GM
J Am Soc Nephrol; 2021 Oct; 32(10):2435-2438. PubMed ID: 34117129
[No Abstract] [Full Text] [Related]
5. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
6. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
7. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.
Speer C; Göth D; Benning L; Buylaert M; Schaier M; Grenz J; Nusshag C; Kälble F; Kreysing M; Reichel P; Töllner M; Hidmark A; Ponath G; Schnitzler P; Zeier M; Süsal C; Morath C; Klein K
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1073-1082. PubMed ID: 34031181
[TBL] [Abstract][Full Text] [Related]
8. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
9. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Naranbhai V; St Denis KJ; Lam EC; Ofoman O; Garcia-Beltran WF; Mairena CB; Bhan AK; Gainor JF; Balazs AB; Iafrate AJ;
Cancer Cell; 2022 Jan; 40(1):103-108.e2. PubMed ID: 34990570
[TBL] [Abstract][Full Text] [Related]
10. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
11. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
[No Abstract] [Full Text] [Related]
12. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
[No Abstract] [Full Text] [Related]
13. Variant-adapted COVID-19 booster vaccines.
Krammer F; Ellebedy AH
Science; 2023 Oct; 382(6667):157-159. PubMed ID: 37824671
[TBL] [Abstract][Full Text] [Related]
14. Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine.
Levin-Iaina N; Angel-Korman A; Leiba A; Peres E; Bryk G; Rapoport V; Katzir Z; Yagil Y; Brosh-Nissimov T
Isr Med Assoc J; 2022 May; 24(5):317-319. PubMed ID: 35598056
[TBL] [Abstract][Full Text] [Related]
15. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.
Longlune N; Nogier MB; Miedougé M; Gabilan C; Cartou C; Seigneuric B; Del Bello A; Marion O; Faguer S; Izopet J; Kamar N
Nephrol Dial Transplant; 2021 Aug; 36(9):1704-1709. PubMed ID: 34057463
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.
El Karoui K; De Vriese AS
Kidney Int; 2022 May; 101(5):883-894. PubMed ID: 35176326
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
18. Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19.
Chan L; Fuca N; Zeldis E; Campbell KN; Shaikh A
Clin J Am Soc Nephrol; 2021 Aug; 16(8):1258-1260. PubMed ID: 34031182
[No Abstract] [Full Text] [Related]
19. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.
Burckhardt RM; Dennehy JJ; Poon LLM; Saif LJ; Enquist LW
J Virol; 2022 Feb; 96(3):e0197321. PubMed ID: 34817198
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice.
Jiang Y; Zhang H; Yu J; Huang D; Zhai L; Li M; Wang Y; Ren Z; Zou L; Zheng Z; Hu H; Zhang J; Zhang B; Zhao W; Yang X; Li B; Shen C
J Med Virol; 2022 Sep; 94(9):4533-4538. PubMed ID: 35614018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
